AbPACER provides a campaign-specific, parent-aware framework for fixed-budget prioritization from affinity-label-blind phage-display NGS data and shows the highest mean recovery among learned methods in both retrospective campaigns.
Abstract
Background Affinity-maturation phage-display next-generation sequencing (NGS) yields more paired single-chain variable fragment clones than can be characterized experimentally, creating a fixed-budget prioritization problem. Read counts provide empirical support rather than direct affinity labels. We developed AbPACER (Antibody Parent-Aware Contextual Evidence Ranker), an affinity-label-blind neural ranker combining parent-relative mutation descriptors, frozen antibody-language-model context, and NGS evidence from related clones. AbPACER is campaign-adaptive rather than zero-shot: for each campaign, it is fitted to paired sequences and round-resolved R1–R3 counts before returning a 384-candidate assay list. We evaluated it in two retrospective phage-display campaigns and separately assessed its supervised mean-squared-error adaptation on AlphaSeq, denoted AbPACER-MSE. Results From frozen top-5% candidate sets containing 16,323 Fas-associated factor 1 (FAF1) and 7,487 vascular endothelial growth factor receptor (VEGFR) clones, each method ranked the complete target-specific set and selected 384 candidates. In FAF1, AbPACER recovered 2.00 ± 0.00 of seven retrospective panel clones, recovering two in every seed, compared with 1/7 by total count, 1.00 ± 0.00 by Ens-Grad CNN, 1.67 ± 1.15 by A2Binder-HL, and 1.33 ± 0.58 by AbAffinity. In VEGFR, AbPACER recovered 2.33 ± 0.58 of three panel clones, the highest observed learned-method mean, whereas total count recovered 3/3. No learned method was uniformly best at broader hypothetical budgets. On the public AlphaSeq common split of 11,670 fixed-test variants, AbPACER-MSE recovered 187.0 ± 2.6 of the true top-384, closely matching AbAffinity (188.0 ± 2.6) and exceeding A2Binder (175.7 ± 6.4) and Ens-Grad CNN (154.0 ± 6.1). AbPACER-MSE updated 1.378 million task-specific parameters, compared with 651.04 million for AbAffinity, and achieved Pearson 0.687 ± 0.003 and Spearman 0.652 ± 0.002. Conclusions AbPACER provides a campaign-specific, parent-aware framework for fixed-budget prioritization from affinity-label-blind phage-display NGS data. At the 384-candidate endpoint, it showed the highest mean recovery among learned methods in both retrospective campaigns. AbPACER-MSE closely matched AbAffinity in true top-384 recovery while updating substantially fewer task-specific parameters. These results motivate prospective evaluation of sequence-conditioned reranking as a complement to count-based prioritization.
AbICL is proposed, an ICL framework for antigen-specific antibody affinity ranking that combines a pretrained structural encoder with a context ranking head and is trained with an episodic meta-training strategy that enables the model to leverage support demonstrations for test-time adaptation without gradient updates.
Zhiyuan Chen, Jing Hu, Junzhe Wang et al.· 0 citations
SAASBench provides a framework for evaluating the model's ability to estimate the specificity of a candidate antibody in relevant settings, indicating that strong performance on traditional affinity benchmarks does not automatically translate into reliable antibody specificity estimation in proteome-derived settings.
Dmitriy Umerenkov, Ivan Poddiakov· Proceedings of the 32nd ACM...· 0 citations
The AIntibody challenge shows that AI can optimize antibodies in defined, biologically grounded regimes, in addition to highlighting critical gaps including affinity prediction and library-inspired antibody design and cross-task generalization.
M. Erasmus, Daniel Bedinger, Elizabeth Hopkins et al.· Nature Biotechnology· 0 citations
CIR-DDG, a lightweight residual adapter that combines a fixed base prediction with 22 interpretable descriptors of cross-chain distance, contact density and site--partner context, is introduced, showing that the learned geometric correction generalizes beyond SKEMPI thermodynamic measurements.
Weizhen Yu, Zhi-Heng Zou, Yonggui Huang et al.· 0 citations
Therapeutic antibody development requires workflows that integrate antigen-reactive clone discovery with efficient humanization and early developability assessment. Here, we combined immune yeast fragment antigen-binding (Fab) display with single-round focused humanization and applied the workflow to antibodies against amyloid-β (Aβ)-derived preparations. Immunization with Aβ1-42 aggregate preparations generated a Fab-display library with a diversity of approximately 3.5 × 108. Magnetic enrichment followed by fluorescence-activated cell sorting (FACS) identified three sequence-distinct immunoglobulin G (IgG)-format candidates, of which CLAB17 and CLAB45 were advanced to humanization. Structure-guided libraries sampled framework positions predicted to support complementarity-determining regions (CDRs) or heavy-and light-chain variable-domain packing, and a single FACS round recovered binding-positive variants CLAB17-h2 and CLAB45-h8. Both retained the parental CDRs and showed increased predicted humanness, favorable computational developability triage profiles, and high purity by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). By enzyme-linked immunosorbent assay (ELISA), CLAB17-h2 showed a lower apparent half-maximal effective concentration (EC50) for Aβ1-42AggreSure, whereas CLAB45-h8 showed a lower apparent EC50 for pyroglutamate-modified Aβ3-42 (AβpE3-42). Because the preparations were not resolved into defined assembly states, these antibodies are considered Aβ-preparation-binding rather than aggregate-state-selective candidates. This workflow provides a practical route from immune-repertoire discovery to binding-positive humanized antibodies.
Youngju Kim, Hayoung Kwon, Jimin Song et al.· bioRxiv· 0 citations
This work designs a biological prior-guided feature fusion framework that integrates pseudo-structural epitope knowledge and CDR-specific attention mechanisms via a mixture-of-experts architecture to effectively capture complex binding landscapes in antibody screening and drug residence time analysis.
G. Luo, Junkai Wang, Sizhe Zhang et al.· Bioinformatics· 0 citations